OBJECTIVE: To prospectively evaluate quality of life (QoL) evolution after sleeve lobectomy and pneumonectomy with the European Organisation for Research and Treatment of Cancer (EORTC) QoL Questionnaire-C30 and LC-13. METHODS: From January 2003 till December 2005, QoL was prospectively recorded after 10 sleeve lobectomies and 20 pneumonectomies. Questionnaires were administered before surgery and 1, 3, 6, and 12 months postoperatively (MPO) with response rates of 100%, 90.0%, 76.7%, 80.0% and 73.3%, respectively. RESULTS: Sleeve lobectomy was characterized by a 1 month temporary decrease in physical and social functioning scores after surgery (1MPO p = 0.026 and p = 0.048, respectively). After sleeve lobectomy, quality of life scores approximated baseline preoperative values 1 month after surgery. In the 12 months follow-up period after pneumonectomy, there was no return to baseline in physical and role functioning (12MPO p = 0.001 and p = 0.011, respectively). Pneumonectomy patients reported a significant increase in postoperative dyspnea (1MPO p = 0.027, 6MPO p = 0.025, 12MPO 0.021), general pain (1MPO p = 0.006, 3MPO p = 0.008, 6MPO p = 0.005, 12MPO p = 0.036), thoracic pain (6MPO p = 0.019) and shoulder dysfunction (6MPO p = 0.04, 12MPO p = 0.026).Comparing both resections, significant differences in evolution of physical functioning (1MPO p = 0.014, 3MPO p = 0.008, 6MPO p = 0.004), role functioning (1MPO p = 0.041), cognitive functioning (6MPO p = 0.005, 12MPO p = 0.013) and shoulder dysfunction (12MPO p = 0.049) were reported in favor of sleeve lobectomy. CONCLUSIONS: The high burden of dyspnea, general pain, thoracic pain and shoulder dysfunction reported after pneumonectomy, is not seen after sleeve lobectomy. In patients with anatomically appropriate early-stage lung cancer, sleeve lobectomy offers better quality of life than does pneumonectomy.
OBJECTIVE: To prospectively evaluate quality of life (QoL) evolution after sleeve lobectomy and pneumonectomy with the European Organisation for Research and Treatment of Cancer (EORTC) QoL Questionnaire-C30 and LC-13. METHODS: From January 2003 till December 2005, QoL was prospectively recorded after 10 sleeve lobectomies and 20 pneumonectomies. Questionnaires were administered before surgery and 1, 3, 6, and 12 months postoperatively (MPO) with response rates of 100%, 90.0%, 76.7%, 80.0% and 73.3%, respectively. RESULTS: Sleeve lobectomy was characterized by a 1 month temporary decrease in physical and social functioning scores after surgery (1MPO p = 0.026 and p = 0.048, respectively). After sleeve lobectomy, quality of life scores approximated baseline preoperative values 1 month after surgery. In the 12 months follow-up period after pneumonectomy, there was no return to baseline in physical and role functioning (12MPO p = 0.001 and p = 0.011, respectively). Pneumonectomy patients reported a significant increase in postoperative dyspnea (1MPO p = 0.027, 6MPO p = 0.025, 12MPO 0.021), general pain (1MPO p = 0.006, 3MPO p = 0.008, 6MPO p = 0.005, 12MPO p = 0.036), thoracic pain (6MPO p = 0.019) and shoulder dysfunction (6MPO p = 0.04, 12MPO p = 0.026).Comparing both resections, significant differences in evolution of physical functioning (1MPO p = 0.014, 3MPO p = 0.008, 6MPO p = 0.004), role functioning (1MPO p = 0.041), cognitive functioning (6MPO p = 0.005, 12MPO p = 0.013) and shoulder dysfunction (12MPO p = 0.049) were reported in favor of sleeve lobectomy. CONCLUSIONS: The high burden of dyspnea, general pain, thoracic pain and shoulder dysfunction reported after pneumonectomy, is not seen after sleeve lobectomy. In patients with anatomically appropriate early-stage lung cancer, sleeve lobectomy offers better quality of life than does pneumonectomy.
Authors: Mark F Berry; Mathias Worni; Xiaofei Wang; David H Harpole; Thomas A D'Amico; Mark W Onaitis Journal: Ann Thorac Surg Date: 2013-11-06 Impact factor: 4.330
Authors: Saana E M Andersson; Ville H S Rauma; Eero I Sihvo; Jari V Räsänen; Ilkka K Ilonen; Jarmo A Salo Journal: J Thorac Dis Date: 2015-10 Impact factor: 2.895
Authors: Sarah M Rausch; Brian D Gonzalez; Matthew M Clark; Christi Patten; Sara Felten; Heshan Liu; Yafei Li; Jeff Sloan; Ping Yang Journal: Lung Cancer Date: 2012-03-29 Impact factor: 5.705
Authors: Virginia Sun; Jae Y Kim; Dan J Raz; Walter Chang; Loretta Erhunmwunsee; Carolina Uranga; Anne Marie Ireland; Karen Reckamp; Brian Tiep; Jennifer Hayter; Michael Lew; Betty Ferrell; Ruth McCorkle Journal: J Cancer Educ Date: 2018-06 Impact factor: 2.037
Authors: Melanie Subramanian; Benjamin D Kozower; Lisa M Brown; Onkar V Khullar; Felix G Fernandez Journal: Ann Thorac Surg Date: 2019-01 Impact factor: 4.330